Approved Merger with Notable Labs and All Other Proposals Merger Expected to Close and Begin Trading as Combined Company Under the NTBL Ticker on Nasdaq Next Week, Subject to Effectiveness of...
MODI™IN, Israel and NEW YORK, Oct. 04, 2023 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) (œVBL), reminds its shareholders to vote in favor of the previously announced proposed merger (the...
Merger with Notable expected to close in mid-October, subject to shareholder approval Special shareholder meeting scheduled for October 12, 2023 MODI™IN, Israel and NEW YORK, Sept. 06, 2023 (GLOBE...
Merger with Notable expected to close in late September or October, subject to VBL’s S-4 registration statement being declared effective and shareholder approval $24.3 million in cash and cash...
MODI’IN, Israel and NEW YORK, May 15, 2023 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) (“VBL”), today announced financial results for the first quarter ended March 31, 2023, and provided a...
VBL Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Update
VBL Therapeutics Announces Closing of Sale of Manufacturing Facility and Certain Related Assets for $7.1 Million in Cash
VBL Therapeutics and Notable Labs Announce Definitive Merger Agreement
After a rocky 2022 for VBL Therapeutics, the biotech is merging with Notable Labs, a cancer-focused platform company that just pulled in $10.3 million from investors.
VBL Therapeutics Announces Agreement to Sell Manufacturing Facility and Certain Related Assets for $7.1 Million in Cash